HUTCHMED (China) Limited Sponsored ADR (HCM)
(Delayed Data from NSDQ)
$18.91 USD
+0.75 (4.13%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $18.89 -0.02 (-0.11%) 5:06 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HCM 18.91 +0.75(4.13%)
Will HCM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for HCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HCM
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
HCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 141.13%: Read This Before Placing a Bet
Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Other News for HCM
UK shareholder meetings calendar - next 21 days
What's Driving HUTCHMED (China) Ltd's Surprising 38% Stock Rally?
HUTCHMED Nears EU Approval for Cancer Drug
Hutchmed notes CHMP's positive opinion for fruiquintinib approval
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda